U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07015346) titled 'Adhesion and Safety of Rotigexole Compared to Neupro(R)' on May 30.
Brief Summary: A non-inferiority open-labelled crossover randomized controlled trial, of two arms, to investigate the adhesiveness and safety of Rotigexole 8 mg/24 hours transdermal patch, manufactured by Eva pharma, Egypt, compared to the innovator product, Neupro(R) 8 mg/ 24 hours transdermal patch, manufactured by UCB Pharma S.A., Belgium, after 24 hours of application
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Idiopathic Parkinson Disease
Intervention:
DRUG: Rotigexole 8 mg
Rotigotine 8 mg
DRUG: Neupro (R) 8 mg
Rotigotine 8 mg
Recr...